

Appendix A: Key to Acronyms

Updated: January 31, 2024

Reviewed: January 31, 2024

Drug Name Abbreviations

Acronym/Abbreviation	Full Name
3TC	lamivudine
ABC	abacavir
ATV	atazanavir
ATV/c	atazanavir/cobicistat
ATV/r	atazanavir/ritonavir
BIC	bictegravir
CAB	cabotegravir
CAB-LA	long-acting cabotegravir; long-acting injectable cabotegravir
COBI, or c	cobicistat
d4T	stavudine
ddC	zalcitabine
ddl	didanosine
DMPA	depot medroxyprogesterone acetate
DOR	doravirine
DRV	darunavir
DRV/c	darunavir/cobicistat
DRV/r	darunavir/ritonavir
DTG	dolutegravir
EFV	efavirenz
ENG	etonogestrel
ETR	etravirine
EVG	elvitegravir
EVG/c	elvitegravir/cobicistat
FPV	fosamprenavir
FPV/r	fosamprenavir/ritonavir

FTC	emtricitabine
FTR	fostemsavir
IBA	ibalizumab-uiyk; ibalizumab
IDV	indinavir
IDV/r	indinavir/ritonavir
INH	isoniazid
LEN	lenacapavir
LNG	levonorgestrel
LPV	lopinavir
LPV/r	lopinavir/ritonavir
MPA	medroxyprogesterone acetate
MVC	maraviroc
NFV	nelfinavir
NVP	nevirapine
RAL	raltegravir
RPV	rilpivirine
RTV, or r	ritonavir
SQV	saquinavir
SQV/r	saquinavir/ritonavir
T-20	enfuvirtide
TAF	tenofovir alafenamide
TDF	tenofovir disoproxil fumarate
TFV	tenofovir
TFV-DP	tenofovir diphosphate
TMP/SMX	trimethoprim/sulfamethoxazole
TPV	tipranavir
TPV/r	tipranavir/ritonavir
ZDV	zidovudine

General Terms

Acronym/Abbreviation	Full Name
AASLD	American Association for the Study of Liver Diseases
ACOG	American College of Obstetricians and Gynecologists
ACTG	AIDS Clinical Trials Group
ALT	alanine aminotransferase
anti-HBc	anti-hepatitis B core antibody
anti-HBs	hepatitis B surface antibody
aOR	adjusted odds ratio
aHR	adjusted hazard ratio
aRR	adjusted risk ratio
ART	antiretroviral therapy
ARV	antiretroviral
AUC	area under the curve
AUC _{0-24h}	area under the curve from 0 to 24 hours
BMC	bone mineral content
BMD	bone mineral density
BMI	body mass index
BHIVA	British HIV Association
BSID-III	Bayley Scales of Infant and Toddler Development, Third Edition
C _{12h}	concentration at 12 hours postdose
C _{24h}	concentration at 24 hours postdose
CAR	chimeric antigen receptor
cCMV	congenital cytomegalovirus
CCR5	C-C chemokine receptor type 5
CD4	CD4 T lymphocyte
CDC	Centers for Disease Control and Prevention
CI	confidence interval
CK	creatine kinase
CL/F	apparent clearance

C _{max}	maximum plasma concentration
C _{min}	minimum plasma concentration
CMV	cytomegalovirus
C _{trough}	trough concentration
COC	combined oral contraceptives
COC/P/R	combined oral contraceptives/patch/ring
CrCl	creatinine clearance
C _{trough}	trough concentration
CYP	cytochrome P450
DAA	direct-acting antiviral
DBS	dried blood spot
DMC	Developmental Milestones Checklist
EC	emergency contraception enteric coated
EC ₉₅	95% maximal effective concentration
EE	ethinyl estradiol
ePPND	enhanced pre- and postnatal development
FDA	U.S. Food and Drug Administration
FDC	fixed-dose combination
GBS	group B streptococcus
GMC	geometric mean concentration
gp	glycoprotein
HAV	hepatitis A virus
HBIG	hepatitis B immune globulin
HBcAb	hepatitis B core antibody
HBeAb	hepatitis B e antibody
HBeAg	hepatitis B e antigen
HBsAb	hepatitis B surface antibody
HBsAg	hepatitis B surface antigen
HBV	hepatitis B virus
HCV	hepatitis C virus

HCAZ	head circumference-for-age z-score
HEU	HIV exposed but uninfected
HD	high dose
HDP	hypertensive disorders of pregnancy
HUU	HIV unexposed and uninfected
HR	hazard ratio
HRSA	Health Resources and Services Administration
HSR	hypersensitivity reaction
IC ₅₀	inhibitory concentration 50%
IDSA	Infectious Diseases Society of America
IGF	insulin-like growth factor
IgG	immunoglobulin G
IgM	immunoglobulin M
IM	intramuscular
INSTI	integrase strand transfer inhibitor
IPV	intimate partner violence
IQR	interquartile range
IRR	incidence rate ratio
IUD	intrauterine device
IUPC	intrauterine pressure catheter
IV	intravenous/intravenously
LA	long-acting
LARC	long-acting reversible contraceptive
LAZ	length-for-age z-score
LBW	low birth weight
LGBTQIA+	lesbian, gay, bisexual, transgender, queer, intersex, asexual, and gender nonconforming
mtDNA	mitochondrial DNA
NAT	nucleic acid test
NE	norethindrone
NHSS	National HIV Surveillance System

NICHD	Eunice Kennedy Shriver National Institute of Child Health and Human Development
NIH	National Institutes of Health
NNRTI	non-nucleoside reverse transcriptase inhibitor
nPEP	non-occupational post-exposure prophylaxis
NPHIV	non-perinatally acquired HIV
NRTI	nucleoside reverse transcriptase inhibitor
NTD	neural tube defect
OARAC	Office of AIDS Research Advisory Council
OI	opportunistic infection
OR	odds ratio
The Panel	The Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission
PBMC	peripheral blood mononuclear cell
PB	physiologically based
PBPK	physiologically based pharmacokinetic
PJP	<i>Pneumocystis jirovecii</i> pneumonia
PCR	polymerase chain reaction
PHIV	perinatally acquired HIV
PI	protease inhibitor
PI/r	ritonavir-boosted protease inhibitor
PK	pharmacokinetic
POC	point of care
POP	progesterone-only oral contraceptive pill
PPI	proton pump inhibitor
PrEP	pre-exposure prophylaxis
PSED	Profile of Social Emotional Development
PTB	preterm birth
RAM	resistance-associated mutation
RCT	randomized controlled trial
RDS	respiratory distress syndrome
ROM	rupture of membranes

RR	relative risk
SGA	small for gestational age
SQ	subcutaneous
STI	sexually transmitted infection
t _{1/2app}	terminal-phase half-life
TB	tuberculosis
Tdap	tetanus, diphtheria, and pertussis
UGT	uridine diphosphate glucuronosyltransferase
WAZ	weight-for-age z-score
WHO	World Health Organization
XR	extended release

Study and Trial Names

Acronym/Abbreviation	Full Name
BAN	Breastfeeding, Antiretrovirals, and Nutrition
DOLPHIN 2	Dolutegravir in Pregnant HIV Women and Their Neonates
EUROCAT	European Surveillance of Congenital Anomalies and Twins
EPPICC	European Pregnancy Paediatric HIV Cohort Collaboration
HPTN	HIV Prevention Trials Network
IMPAACT	International Maternal Pediatric Adolescent AIDS Clinical Trials
MOTIVATE	Mother–Infant Visit Adherence and Treatment Engagement
PACTG	Pediatric AIDS Clinical Trials Group
PANNA	Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women
PARTNER	Partners of People on ART-A New Evaluation of the Risks
PHACS	Pediatric HIV/AIDS Cohort Study
PROMISE	Promoting Maternal and Infant Survival Everywhere
SMARTT	Surveillance and Monitoring for ART Toxicities
START	Strategic Timing of AntiRetroviral Treatment
VESTED	Virologic Efficacy and Safety of ART Combinations with TAF/TDF, EFV, and DTG